The antitumor effects of an arsthinol-cyclodextrin complex in a heterotopic mouse model of glioma

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 560-568

  Becherirat, Selma ^a   Lanhers, Marie Claire ^b   Socha, Marie ^a   Yemloul, Mehdi ^b   Astier, Alain ^c   Loboda, Caroline ^a   Aniceto, Natália ^a   Gibaud, Stéphane ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Arsenic; Brain tumors; Cancer; Cyclodextrin; Glioblastoma; Glioma

Indexed keywords

ARSENIC TRIOXIDE; ARSTHINOL; CYCLODEXTRIN; MELARSOPROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GLIOMA; IN VIVO STUDY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; XENOGRAFT;

ARSENIC; BRAIN TUMORS; CANCER; CYCLODEXTRIN; GLIOBLASTOMA; GLIOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BETA-CYCLODEXTRINS; BRAIN NEOPLASMS; CELL LINE, TUMOR; EXCIPIENTS; FEMALE; GLIOMA; HUMANS; INJECTIONS, INTRAPERITONEAL; MAGNETIC RESONANCE SPECTROSCOPY; MELARSOPROL; MICE; MICE, NUDE; OXIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888370315     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.06.021     Document Type: Article

References (34)

1. N. Howlader, A. Noone, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, S. Altekruse, C. Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M. Eisner, D. Lewis, H. Chen, E. Feuer, K. Cronin, SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, < http://seer.cancer.gov/csr/1975-2009-pops09/ >, based on November 2011 SEER data submission, posted to the SEER web site, April 2012, 2012.
2. C. Corle, M. Makale, and S. Kesari Cell phones and glioma risk: a review of the evidence J. Neuro-oncol. 106 2012 1 13
3. H.-W. Chiu, Y.-S. Ho, and Y.-J. Wang Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin J. Mol. Med. 89 2011 927 941
4. 3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status Int. J. Oncol. 21 2002 49 55
5. F. Jiang, X. Zhang, S. Kalkanis, Z. Zhang, H. Yang, M. Katakowski, X. Hong, X. Zheng, Z. Zhu, and M. Chopp Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma Photochem. Photobiol. 84 2008 128 137
6. Anonyme New and nonofficial remedies; arsthinol J Am. Med. Assoc. 152 1953 531
7. S. Gibaud, and G. Jaouen Arsenic-based drugs: from Fowler's solution to modern anticancer chemotherapy Top. Organomet. Chem. 32 2010 1 20
8. A. Astier, S. Gibaud, Use of Organoarsenic or Oraganoantimony Derivatives for their Anticancer Properties, WO Patent 2005/034935 A1, 2005.
9. S. Gibaud, R. Alfonsi, P. Mutzenhardt, I. Fries, and A. Astier (2-Phenyl-[1,3,2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity J. Organomet. Chem. 691 2006 1081 1084
10. S. Gibaud, and A. Astier Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs Ann. Pharm. Fr. 65 2007 162 168
11. I. Ajana, A. Astier, and S. Gibaud Arsthinol for the treatment of leukaemia: a new look at an old treatment Oncologie 11 2009 S34 S35
12. I. Ajana, A. Astier, M.C. Lanhers, B. Demoré, M. Socha, and S. Gibaud 1217 Dithiarsolanes in the treatment of glioma: in vitro activity on U87 cell line and brain concentrations on a mouse model Eur. J. Cancer Suppl. 7 2009 125
13. I. Ajana, A. Astier, and S. Gibaud Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells J. Pharm. Pharmacol. 61 2009 1295 1301
14. S. Gibaud, S.B. Zirar, P. Mutzenhardt, I. Fries, and A. Astier Melarsoprol-cyclodextrins inclusion complexes Int. J. Pharm. 306 2005 107 121
15. J. Rodgers, A. Jones, S. Gibaud, B. Bradley, C. McCabe, M.P. Barrett, G. Gettinby, and P.G.E. Kennedy Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human african trypanosomiasis Plos Neglect. Trop. Dis. 5 2011 e1308
16. I. Ajana, A. Astier, and S. Gibaud Speciation of arsenic in urine following intravenous administration of arsthinol in mice Eur. J. Drug Metabol. Pharmacokinet. 35 2010 59 65
17. E. Friedheim, Substituted [1,3,5-triazinyl-(6)]-aminophenyl-arsonic acids and Process for Manufacture of Same, United States Patent 2,295,574, 1942.
18. E. Friedheim, Heterocyclic Metal and Sulfur Organic Compounds, United States Patent, 1953.
19. T. Higuchi, and K.A. Connors Phase-solubility techniques Adv. Anal. Chem. Instrum. 4 1965 117 212
20. C. Hiskey, and F. Cantwell Ultraviolet spectrum correlations with the conjugate acid-base species of acetarsone and arsthinol J. Pharm. Sci. 57 1968 2105 2111
21. American Chemical Society Committee on Analytical Reagents, Reagent Chemicals: Specifications and Procedures, Oxford University Press, Washington, USA, 2006.
22. C. Kahle, and U. Holzgrabe Determination of binding constants of cyclodextrin inclusion complexes with amino acids and dipeptides by potentiometric titration Chirality 16 2004 509 515
23. S. Elliot, and B. Loper Improved absorption tube for arsenic determinations Anal. Chem. 46 1974 2256 2257
24. S. Soignet, W. Tong, S. Hirschfeld, and R. Warrell Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia Cancer Chemother. Pharmacol. 44 1999 417 421
25. T. Kanzawa, Y. Kondo, H. Ito, S. Kondo, and I. Germano Induction of autophagic cell death in malignant glioma cells by arsenic trioxide Cancer Res. 63 2003 2103 2108
26. T. Kanzawa, L. Zhang, L. Xiao, I. Germano, Y. Kondo, and S. Kondo Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3 Oncogene 24 2005 980 991
27. I. Brandariz, and E. Iglesias Potentiometric characterisation of cyclodextrin inclusion complexes of local anaesthetics Supramol. Chem. 23 2011 607 614
28. 1H-NMR and molecular modeling studies J. Incl. Phenom. Macrocycl. Chem. 57 2007 519 523
29. N. Funasaki, M. Nagaoka, and S. Hirota Competitive potentiometric determination of binding constants between alpha-cyclodextrin and 1-alkanols Anal. Chim. Acta 531 2005 147 151
30. E. Junquera, and E. Aicart A fluorimetric, potentiometric and conductimetric study of the aqueous solutions of naproxen and its association with hydroxypropyl-beta-cyclodextrin Int. J. Pharm. 176 1999 169 178
31. J.P. Diard, E. Saint-Aman, and D. Serve Potentiometric association constant measurements of α, β or γ-cyclodextrin complexes involving iodide, tri-iodide or iodine species J. Electroanal. Chem. Interfacial Electrochem. 189 1985 113 120
32. K.A. Connors, and J.M. Lipari Effect of cycloamyloses on apparent dissociation constants of carboxylic acids and phenols: equilibrium analytical selectivity induced by complex formation J. Pharm. Sci. 65 1976 379 383
33. H. Brun, M. Paul, N. Razzouq, M. Binhas, S. Gibaud, and A. Astier Cyclodextrin inclusion complexes of the central analgesic drug nefopam Drug Dev. Ind. Pharm. 32 2006 1123 1134
34. S. Ben Zirar, S. Gibaud, A. Camut, and A. Astier Pharmacokinetics and tissue distribution of the antileukaemic organoarsenicals arsthinol and melarsoprol in mice J. Organomet. Chem. 692 2007 1348 1352